Haplo-PBSC+Cord vs Haplo-PBSC+BM for Hematological Malignancies Undergoing Allo-HSCT
Study Details
Study Description
Brief Summary
The objective of this study was to explore whether the combination with umbilical cord blood (UCB) is associated with superior disease-free survival (DFS) in the setting of haploidentical donors (HID) transplantation.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 3 |
Detailed Description
The main causes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) failure are primary disease relapse and transplant-related complications, especially relapse. In recent years, with the development of transplantation technology, alternative donors such as HID and UCB have been widely used. But, these alternative donors are associated with high incidences of transplant-related complications and mortalities when compared with human leukocyte antigen (HLA)-matched donors. Some studies suggeted that mixed grafts might overcome the disadvantages of a single alternative graft. UCB transplant (UCBT) supported by third-party HID or HID transplants supported by third-party UCB has been reported to have rapid engraftment and low incidences of graft-versus-host-disease (GVHD), making survival improvement. However, most of these results came from single-arm studies. The comparative studies between haplo-PBSC+Cord and haplo-PBSC+BM are scarce in the setting of HID transplantation. In a retrospective study, the investigators found haplo-PBSC+Cord transplantation has superior DFS than haplo-PBSC+BM in hematological malignancies. To further confirmed this conclusion, the investigators plan to conduct a prospective, multicenter, phase 3 randomized controlled trial.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Haplo-PBSC+Cord group The third party UCB will be infused the day after infusion of PBSCs from HID. |
Other: PBSCs
PBSCs harvest is performed from day 5 of G-CSF to obtain at least 7.0×10^8 total nucleated cells/kg recipient ideal body weight.
Other: Cord
The criteria for cord selection included the following: (1) ≥3 of 6 HLA loci , (2) blood type matches, (3) contained a minimum cell count of 0.3×10^8 nucleated cells/kg and 0.15×10^6 CD34-positive cells/kg before freezing. The third party UCB will be infused the day after infusion of PBSCs.
|
| Active Comparator: Haplo-PBSC+BM group The BMSCs from the same HID will be infused the day after infusion of PBSCs. |
Other: PBSCs
PBSCs harvest is performed from day 5 of G-CSF to obtain at least 7.0×10^8 total nucleated cells/kg recipient ideal body weight.
Other: BMSCs
BMSCs of donor will be collected and infused at least 0.5×10^8 total nucleated cells/kg recipient ideal body weight the day after PBSCs infusion.
|
Outcome Measures
Primary Outcome Measures
- Disease-free survival (DFS) [1 year]
Secondary Outcome Measures
- Relapse rate [1 year]
- Overall survival (OS) [1 year]
- The cumulative incidence of hematopoietic engraftment. [30 days post-transplantation]
Hematopoietic engraftment includes the time of neutrophil and platelet engraftment. Neutrophil engraftment was defined as the first of two consecutive days with an absolute neutrophil count in the peripheral blood exceeding 0.5 × 10^9/L and the platelet engraftment was defined as the first of 3 days with an absolute platelet count exceeding 20 × 10^9 /L without transfusion support.
- The cumulative incidence of acute graft-versus-host-disease (GVHD) [100 days post-transplantation]
Acutue GVHD was defined according to the 1994 consensus conference on acute GVHD grading and graded from I to IV.
- The cumulative incidence of chronic GVHD [1 year]
Chronic GVHD was graded as mild, moderate and severe according to the national institutes of health consensus development project on criteria for clinical trials in chronic GVHD: the 2014 diagnosis and staging working group report.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients with hematologic malignancies undergoing first HID allo-HSCT
-
Age 18 to 65 years old with ECOG performance status 0-2
-
Received myeloablative conditioning regimens
-
Sign informed consent form, have the ability to comply with study and follow-up procedures
Exclusion Criteria:
-
Received PBSCs as only grafts
-
Acute leukemia transformed from a myeloproliferative tumor
-
Cardiac dysfunction (particularly congestive heart failure, unstable coronary artery disease and serious cardiac ventricular arrhythmias requiring antiarrhythmic therapy)
-
Respiratory failure ( PaO2 ≤60mmHg)
-
Hepatic abnormalities (total bilirubin ≥3 mg/dL, aminotransferase >2 times the upper limit of normal)
-
Renal dysfunction (creatinine clearance rate < 30 mL/min)
-
ECOG performance status 3, 4 or 5
-
With any conditions not suitable for the trial (investigators' decision)
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Department of Hematology,Nanfang Hospital, Southern Medical University | Guangzhou | Guangdong | China | 510515 |
Sponsors and Collaborators
- Nanfang Hospital of Southern Medical University
- Anhui Provincial People's Hospital Affiliated to University of Science and Technology of China
- The Seventh Affiliated Hospital of Sun Yat-sen University
- The First People's Hospital of Guangzhou
- The First People's Hospital of Chenzhou
Investigators
- Principal Investigator: Qifa Liu, Nanfang Hospital of Southern Medical University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- Haplo+Cord vs Haplo-2022